Therini Bio has filed a notice of an exempt offering of securities to raise $54,617,530.00 in New Equity and Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Therini Bio is raising $54,617,530.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Daniel Burgess played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Therini Bio
Therini Bio, Inc. is a biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction. Our approach will be generally applicable across a range of inflammatory diseases including peripheral indications. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.
To learn more about Therini Bio, visit http://www.therinibio.com/
Contact:
Daniel Burgess, President and Chief Executive Officer
858-414-1105
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.